Found: 20
Select item for more details and to access through your institution.
Comprehensive analysis of the mechanism and treatment significance of Mucins in lung cancer.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2020, v. 39, n. 1, p. N.PAG, doi. 10.1186/s13046-020-01662-3
- By:
- Publication type:
- Article
High expression of HSP60 and survivin predicts poor prognosis for oral squamous cell carcinoma patients.
- Published in:
- BMC Oral Health, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12903-023-03311-5
- By:
- Publication type:
- Article
Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol.
- Published in:
- Molecular Oncology, 2020, v. 14, n. 4, p. 882, doi. 10.1002/1878-0261.12645
- By:
- Publication type:
- Article
Increased expression of FAT4 suppress metastasis of lung adenocarcinoma through regulating MAPK pathway and associated with immune cells infiltration.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 2, p. 1616, doi. 10.1002/cam4.4977
- By:
- Publication type:
- Article
Overexpression of p-Akt, p-mTOR and p-eIF4E proteins associates with metastasis and unfavorable prognosis in non-small cell lung cancer.
- Published in:
- PLoS ONE, 2020, v. 15, n. 2, p. 1, doi. 10.1371/journal.pone.0227768
- By:
- Publication type:
- Article
G3BP1 Interact with JAK2 mRNA to Promote the Malignant Progression of Nasopharyngeal Carcinoma via Activating JAK2/STAT3 Signaling Pathway.
- Published in:
- International Journal of Biological Sciences, 2024, v. 20, n. 1, p. 94, doi. 10.7150/ijbs.85341
- By:
- Publication type:
- Article
YAP1 synergize with YY1 transcriptional co-repress DUSP1 to induce osimertinib resistant by activating the EGFR/MAPK pathway and abrogating autophagy in non-small cell lung cancer.
- Published in:
- International Journal of Biological Sciences, 2023, v. 19, n. 8, p. 2458, doi. 10.7150/ijbs.79965
- By:
- Publication type:
- Article
The role of microRNAs in resistance to targeted treatments of non-small cell lung cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
miR-4634 augments the anti-tumor effects of RAD001 and associates well with clinical prognosis of non-small cell lung cancer.
- Published in:
- Scientific Reports, 2020, v. 10, n. 1, p. N.PAG, doi. 10.1038/s41598-020-70157-0
- By:
- Publication type:
- Article
Efficacy of indocyanine green fluorescence‐guided inguinal lymph node dissection for penile cancer: a randomised trial.
- Published in:
- BJU International, 2024, v. 133, n. 4, p. 442, doi. 10.1111/bju.16231
- By:
- Publication type:
- Article
Exosome-mediated miR-7-5p delivery enhances the anticancer effect of Everolimus via blocking MNK/eIF4E axis in non-small cell lung cancer.
- Published in:
- Cell Death & Disease, 2022, v. 13, n. 2, p. 1, doi. 10.1038/s41419-022-04565-7
- By:
- Publication type:
- Article
USP5 facilitates non-small cell lung cancer progression through stabilization of PD-L1.
- Published in:
- Cell Death & Disease, 2021, v. 12, n. 11, p. 1, doi. 10.1038/s41419-021-04356-6
- By:
- Publication type:
- Article
AXL in cancer: a modulator of drug resistance and therapeutic target.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2023, p. 1, doi. 10.1186/s13046-023-02726-w
- By:
- Publication type:
- Article
Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589).
- Published in:
- 2020
- By:
- Publication type:
- journal article
Overexpressed p-S6 associates with lymph node metastasis and predicts poor prognosis in non-small cell lung cancer.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Hyperprogressive Disease After Immunotherapy: A Case Report of Pulmonary Enteric Adenocarcinoma.
- Published in:
- 2022
- By:
- Publication type:
- Case Study
Elevated expression of mcl-1 inhibits apoptosis and predicts poor prognosis in patients with surgically resected non-small cell lung cancer.
- Published in:
- Diagnostic Pathology, 2019, v. 14, n. 1, p. N.PAG, doi. 10.1186/s13000-019-0884-3
- By:
- Publication type:
- Article
Overcoming acquired resistance of epidermal growth factor receptor‐mutant non–small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589).
- Published in:
- Cancer (0008543X), 2020, v. 126, n. 9, p. 2024, doi. 10.1002/cncr.32744
- By:
- Publication type:
- Article
ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses.
- Published in:
- Frontiers in Oncology, 2020, v. 10, p. 1, doi. 10.3389/fonc.2020.00515
- By:
- Publication type:
- Article